SCHEMBL1923318

SCHEMBL1923318

COc1ccc(NC(=O)Cn2cc(-c3ccc(OC)cc3)c(=O)c3ccc(C)cc32)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.53
IDO1 P14902 1/20 0.52
TUBB4A P04350 1/20 0.52
TUBB P07437 1/20 0.52
TUBA3C P0DPH7 1/20 0.52
TUBA1B P68363 1/20 0.52
TUBA4A P68366 1/20 0.52
TUBB4B P68371 1/20 0.52
TUBB3 Q13509 1/20 0.52
TUBB2A Q13885 1/20 0.52
TUBB8 Q3ZCM7 1/20 0.52
TUBA3E Q6PEY2 1/20 0.52
TUBA1A Q71U36 1/20 0.52
TUBA1C Q9BQE3 1/20 0.52
TUBB6 Q9BUF5 1/20 0.52
TUBB2B Q9BVA1 1/20 0.52
TUBB1 Q9H4B7 1/20 0.52
KDM4E B2RXH2 1/20 0.51
PSMD14 O00487 1/20 0.51
ALDH1A1 P00352 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1923426 0.95 KDM4E (0.53) MAPTTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1923296 0.93 MAPT (0.49) MAPTIDO1TUBB4ATUBBTUBA3C
SCHEMBL4406521 0.88 MAPT (0.59) MAPTTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1923408 0.88 TP53 (0.46) MAPTIDO1KDM4EPSMD14ALDH1A1
SCHEMBL1925179 0.87 EGFR (0.48) MAPTKDM4EALDH1A1RXFP1POLB
SCHEMBL1923602 0.86 CPT2 (0.55) MAPTALDH1A1RXFP1TP53MEN1
SCHEMBL1923329 0.86 MARK4 (0.53) MAPTALDH1A1RXFP1TP53MEN1
SCHEMBL1924231 0.86 PTGDR2 (0.44) MAPTKDM4EALDH1A1RXFP1POLB
SCHEMBL1923324 0.86 MAPT (0.44) MAPTIDO1TUBB4ATUBBTUBA3C
SCHEMBL1923669 0.85 POLB (0.46) MAPTIDO1TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064185-B1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2011-06-08 EP claimed
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2010-07-01 US claimed
EP-2064185-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS Ferrer Internacional, S.A. (ES) 2009-06-03 EP claimed
WO-2008017710-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL S.A. (ES) 2008-02-14 WO claimed
EP-1886996-A1 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-13 EP claimed
EP-2064185-B1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2011-06-08 EP disclosed
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2010-07-01 US disclosed
EP-1886996-A1 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS GABRA1, GABRA4, GABRA2 MAPT 1569/4885IDO1 1338/4885TUBB4A 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.